Compound ID | 3061
Ertapenem + Zidebactam
Synonym(s): WCK 6777
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against Enterobacteriaceae and Pseudomonas aeruginosa; indicated for urinary tract infection |
| Combined with other compounds: | Yes |
| Description: | Semisynthetic compound; carbapenem and non-beta-lactam bicyclo-acyl hydrazide |
| Institute where first reported: | Wockhardt Ltd |
| Year first mentioned: | 2022 |
| Highest development stage: | Phase 1 (NCT05645757) |
| Development status: | Active (as of 2024) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/150610 |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.